New NephSAP Issue - "Chronic Kidney Disease and Progression"

By ASN Staff

NephSAP Volume 18, Number 4, September 2019

Chronic Kidney Disease and Progression

CKD burden continue to remain high in the United States and Medicare spending for all beneficiaries who had CKD exceeded $79 billion in 2016. The 2019 Chronic Kidney Disease issue of NephSAP guides readers through the latest advances in clinical research for this common and costly disease. This issue of NephSAP provides a background of the clinical research published during the years 2017 and 2018, and covers several major areas of CKD research: epidemiology, biomarkers relevant to incidence and progression, genetic variants, cardiovascular disease, weight loss interventions, and novel tools to improve CKD care measures. There have been exciting developments in our understanding of the pathogenesis and treatment options for diabetic kidney disease in the recent years. Several relevant clinical trials that demonstrated improvements in outcomes for those with diabetic kidney disease  have been highlighted in this issue. Along with it, several novel risk factors for progression of kidney disease have also been discussed. Cardiovascular disease remains the principal cause of death for adults with CKD. This NephSAP outlines advances in management of atrial fibrillation and the use of device therapy in CKD. The epidemiology and conseqeuences of pulmonary hypertension, peripheral artery disease and congnitive function in those with CKD are also discussed. Clinical practitioners will also be provided with insight into topics ranging from management of obesity along with understanding about novel methodology and tools that have been tested to help improve CKD care delivery. Finally, readers can also test their knowledge with a series of 30 questions.
 

Learning Objectives

  1. Appraise clinical trial data examining the renal effects of various oral hypoglycemic agents
  2. Explain clinical evidence regarding CKD related complications
  3. Evaluate new developments related to clinical risk factors and emerging biomarkers for identification and treatment of cardiovascular disease in CKD
  4. Discuss new data about weight loss interventions in CKD
  5. Analyze novel methods and tools that improve care delivery models for CKD
Category:
Subcategory:
Author:
ASN Staff
Article Image:
Body:

NephSAP Volume 18, Number 4, September 2019

Chronic Kidney Disease and Progression

CKD burden continue to remain high in the United States and Medicare spending for all beneficiaries who had CKD exceeded $79 billion in 2016. The 2019 Chronic Kidney Disease issue of NephSAP guides readers through the latest advances in clinical research for this common and costly disease. This issue of NephSAP provides a background of the clinical research published during the years 2017 and 2018, and covers several major areas of CKD research: epidemiology, biomarkers relevant to incidence and progression, genetic variants, cardiovascular disease, weight loss interventions, and novel tools to improve CKD care measures. There have been exciting developments in our understanding of the pathogenesis and treatment options for diabetic kidney disease in the recent years. Several relevant clinical trials that demonstrated improvements in outcomes for those with diabetic kidney disease  have been highlighted in this issue. Along with it, several novel risk factors for progression of kidney disease have also been discussed. Cardiovascular disease remains the principal cause of death for adults with CKD. This NephSAP outlines advances in management of atrial fibrillation and the use of device therapy in CKD. The epidemiology and conseqeuences of pulmonary hypertension, peripheral artery disease and congnitive function in those with CKD are also discussed. Clinical practitioners will also be provided with insight into topics ranging from management of obesity along with understanding about novel methodology and tools that have been tested to help improve CKD care delivery. Finally, readers can also test their knowledge with a series of 30 questions.
 

Learning Objectives

  1. Appraise clinical trial data examining the renal effects of various oral hypoglycemic agents
  2. Explain clinical evidence regarding CKD related complications
  3. Evaluate new developments related to clinical risk factors and emerging biomarkers for identification and treatment of cardiovascular disease in CKD
  4. Discuss new data about weight loss interventions in CKD
  5. Analyze novel methods and tools that improve care delivery models for CKD
Date:
Friday, September 20, 2019